ASX Announcements

Published On 19 November

Dr Lindner as Europe CEO and Prof Waugh as Senior Advisor

Dr Lindner as Europe CEO and Prof Waugh as Senior Advisor

Learn more
Published On 01 November

Quarterly Appendix 4C and Business updates

Quarterly Appendix 4C and Business updates

Learn more
Published On 30 October

Notice of Annual General Meeting/Proxy Form

Notice of Annual General Meeting/Proxy Form

Learn more
Published On 23 October

Initial Director’s Interest Notice – Dr Gary W Pace

Initial Director’s Interest Notice – Dr Gary W Pace

Learn more
Published On 23 October

Appointment of Dr. Gary W. Pace as director

Appointment of Dr. Gary W. Pace as director

Learn more
Published On 22 October

Assoc Prof Iyer as Chair of IVQ Medical Advisory Board

Assoc Prof Iyer as Chair of IVQ Medical Advisory Board

Learn more
Published On 28 September

Annual Report to shareholders

Annual Report to shareholders

Learn more
Published On 28 September

Appendix 4G

Appendix 4G

Learn more
Published On 10 September

Notice of Ceasing to be a Substantial Holder

Notice of Ceasing to be a Substantial Holder

Learn more
Published On 04 September

Business updates

Business updates

Learn more
Published On 31 August

Preliminary Final Report

Appendix 4E for the year ended 30 June 2018

Learn more
Published On 28 August

Change in substantial holding

Notice of change of interests of substantial holder

Learn more
Published On 31 July

Appendix 4C – quarterly

Appendix 4C – quarterly

Learn more
Published On 17 July

Expiry of Unlisted Warrants

Expiry of Unlisted Warrants

Learn more
Published On 02 July

Expiry of Unlisted Warrants

Expiry of Unlisted Warrants

Learn more
Published On 28 June

Cleansing statement

Cleansing statement

Learn more
Published On 28 June

Appendix 3B

Appendix 3B OK

Learn more
Published On 26 June

Proposed issue of securities

Proposed issue of securities

Learn more
Published On 25 May

Change in substantial holding

Change in substantial holding

Learn more
Published On 30 April

Appendix 4C – quarterly

Appendix 4C – quarterly

Learn more
Published On 27 April

Appendix 4G

Appendix 4G

Learn more
Published On 13 April

IVQ launches Personalised Cancer Screening Service Onco-PDO

Invitrocue launches world’s first commercial Personalised Cancer Screening Service: Onco-PDO™

Learn more
Published On 28 February

Half Yearly Report and Accounts

Half Yearly Report and Accounts

Learn more
Published On 26 February

Grant from Northern Ireland to commercialize Onco-PDO

Invitrocue secures grant from Northern Ireland to commercialise Onco-PDO

Learn more
Published On 23 February

Investor Presentation

Investor presentation

Learn more
Published On 20 February

Change of Director’s Interest Notice – Jamie Khoo

Change of Director’s Interest Notice – Jamie Khoo

Learn more
Published On 20 February

Change of Director’s Interest Notice – Steven Fang

Change of Director’s Interest Notice – Steven Fang

Learn more
Published On 20 February

Change of Director’s Interest Notice – Hanry Yu

Change of Director’s Interest Notice – Hanry Yu

Learn more
Published On 14 February

Change of Director’s Interest Notice

Change of Director’s Interest Notice

Learn more
Published On 14 February

Change of Director’s Interest Notice

Change of Director’s Interest Notice

Learn more
Published On 14 February

Change of Director’s Interest Notice

Change of Director’s Interest Notice

Learn more
Published On 14 February

Change of Director’s Interest Notice

Change of Director’s Interest Notice

Learn more
Published On 14 February

Change of Director’s Interest Notice

Change of Director’s Interest Notice

Learn more
Published On 12 February

Initial Director’s Interest Notice

Initial Director’s Interest Notice

Learn more
Published On 09 February

Appendix 3B

Appendix 3B

Learn more
Published On 07 February

Appointment of non-executive director

Appointment of non-executive director

Learn more
Published On 31 January

Appendix 4C & quarterly business update

Appendix 4C & quarterly business update

Learn more
Published On 29 January

Appendix 3B

Appendix 3B – New issue announcement, application for quotation of additonal securities and agreement

Learn more
Published On 18 January

IVQ successfully grows liver cancer organoids

Invitrocue further validates its Onco-PDO technology platform through the successful growth of 14 liver cancer organoids

Learn more
Published On 15 January

Escrow Release

Escrow Release  

Learn more
Published On 08 December

Cleansing Statement

Cleansing Statement

Learn more
Published On 08 December

Appendix 3B

Appendix 3B – New issue announcement, application for quotation of additonal securities and agreement

Learn more
Published On 07 December

Proposed Issue of Securities

Proposed Issue of Securities

Learn more
Published On 30 November

Results of Annual General Meeting

Results of Annual General Meeting

Learn more
Published On 30 November

2017 AGM Presentation

2017 AGM Presentation

Learn more
Published On 13 November

Cleansing Statement

Cleansing Statement

Learn more
Published On 13 November

Appendix 3B

Appendix 3B – New issue announcement, application for quotation of additonal securities and agreement

Learn more
Published On 10 November

Proposed issue of securities

Proposed issue of securities

Learn more
Published On 31 October

Quarterly Business Update and Investor Calls

Highlights for the quarter ending September 2017 

Learn more
Published On 30 October

Appendix 4C – Quarterly Report

Appendix 4C – Quarterly Report

Learn more
Published On 30 October

Notice of Annual General Meeting/Proxy Form

Notice of Annual General Meeting and Explanatory Statement

Learn more
Published On 29 September

Annual Report to Shareholders

Annual Report For The Period Ended 30 June 20167

Learn more
Published On 28 September

Appointments to the Management Team

Invitrocue announces appointments to the management team

Learn more
Published On 31 August

Preliminary Final Report

Preliminary Final Report: Download here.  

Learn more
Published On 29 August

IVQ receives award from Singapore government IP office

IVQ receives award from Singapore government IP office

Learn more
Published On 29 August

Investor Presentation

Investor Presentation

Learn more
Published On 31 July

Appendix 4C – Quarterly Report and Business Update

Appendix 4C – Quarterly Report and Business Update Investor Call  

Learn more
Published On 24 July

Launch of New Joint Innovation Laboratory to Advance Personalised Medicine for Cancer Treatment

L-R: Dr Benjamin Seet, Executive Director of the Biomedical Research Council, A*STAR; His Excellency Bruce Gosper, the Australian High Commissioner to Singapore; Dr Steven Fang, Chief Executive Officer / Founder, Invitrocue Ltd; The Hon Martin Hamilton Smith, Minister for Trade and Investment, South Australian Government; Dr Raj Thampuran, Managing Director, A*STAR; Professor Ng Huck Hui, […]

Learn more
Published On 03 July

Invitrocue to work with Garvan Institute to Progress Personalised Real-time Screening of Cancer Drugs

July 03, 2017 – Invitrocue Limited (ASX:IVQ), a leading healthcare bio-analytic solutions providers, is pleased to announce that it has been granted Human Research Ethics Committee approval to understand a cancer research study with Sydney’s Garvan Institute of Medical Research, to provide further clinical validation of Invitrocue technology for use in personalised real-time screening of […]

Learn more
Published On 30 June

Cleansing Statement

Cleansing Statement

Learn more
Published On 30 June

Appendix 3B – New Issue Announcement

Appendix 3B

Learn more
Published On 29 June

Proposed Issue of Securities

Proposed Issue of Securities

Learn more
Published On 26 May

Corporate Governance Statement

Corporate Governance Statement and is accessible at the Corporate Governance Page.

Learn more
Published On 22 May

Invitrocue Expands Into In-Vitro Skin and Wound Healing Assays

22 May, 2017 – Invitrocue (ASX:IVQ) announced today that it will be expanding its cell-based assaying business into skin and wound healing. Invitrocue will develop robust and easy-to-use in vitro assays to assess the safety and effectiveness of consumer antiseptics and over-the-counter (OTC) wound dressing products. Invitrocue has signed a Master Services Agreement with Mundipharma […]

Learn more
Published On 11 May

Response to ASX Appendix 4C Query

Response to ASX Appendix 4C Query

Learn more
Published On 28 April

Appendix 4C – Quarterly Report

Appendix 4C – Quarterly report for entities subjected to Listing Rule 4.7B: Download here.

Learn more
Published On 28 February

Appendix 4D – Half Yearly Report and Accounts

Appendix 4D – Half Yearly Report and Accounts

Learn more
Published On 23 February

Invitrocue Signs Research Collaboration Agreement with the Garvan Institute of Medical Research

February 23, 2017 – Invitrocue (ASX: IVQ) is pleased to announce that the company has signed a Collaborative Research Master Agreement with the Garvan Institute of Medical Research. The aim of the collaboration is to provide further medical validation of Invitrocue’s technology for use in personalised real time screening of cancer drugs. It is envisaged […]

Learn more
Published On 30 January

Appendix 4C – Quarterly Report

Appendix 4C – Quarterly report for entities subjected to Listing Rule 4.7B: Download here.

Learn more
Published On 03 January

Escrow Release

Escrow Release Click here to download.

Learn more
Published On 30 November

Results of Annual General Meeting 2016

Click here to view the results of the AGM 2016.

Learn more
Published On 24 November

Invitrocue Appoints DasGupta Ramanuj, Ph.D as Senior Scientific Director

23 November 2016 – Invitrocue (ASX:IVQ) is pleased to announce that Dr. Ramanuj DasGupta, Ph.D will be joining the company as Senior Scientific Director on 1 December 2016. Dr. DasGupta is a highly regarded professor in New York University School of Medicine with more than a decade of experience in cancer research and drug discovery. […]

Learn more
Published On 31 October

Appendix 4C – Quarterly Report

Appendix 4C – Quarterly report for entities subjected to Listing Rule 4.7B: Download here.

Learn more
Published On 28 October

Annual General Meeting 2016

Invitrocue (ASX:IVQ) will be holding our inaugural AGM on the 30th of  November. Click here for AGM Notice.

Learn more
Published On 24 October

Invitrocue Signs Research Collaboration Agreement with Genome Institute of Singapore for Colorectal Cancer Organoids

October 24, 2016 – Invitrocue (ASX:IVQ) announced a collaboration agreement with the  Cancer Therapeutics and Stratified Oncology Group at the Genome Institute of Singapore (GIS), A*STAR. Invitrocue and GIS will jointly conduct a pilot feasibility study using Invitrocue’s cell-based 3D scaffolding technology (Onco-PDO™) to culture colorectal cancer organoids. The aim of the study is to […]

Learn more
Published On 30 September

Annual Report For The Period Ended 30 June 2016

Annual Report Click here to view on ASX. Click here to view on Google Drive.

Learn more
Published On 08 September

Addendum To Appendix 4E

September 08, 2016 – Invitrocue Limited (ASX: IVQ) has provided the following addendum to the Appendix 4E issued on 31 August for the period ended 30 June 2016. Reverse takeover (RTO) listing on 27 January 2016 During the year, Invitrocue Limited acquired all the shares of Invitrocue Pte Ltd by means of a scrip offer. […]

Learn more
Published On 06 September

InvitroCue Awarded A*STAR Tender

September 05, 2016 – InvitroCue (ASX:IVQ) has been awarded a tender by the Institute of Bioengineering and Nanotechnology, Agency for Science, Technology and Research (A*STAR), to supply and deliver Hepatocue 96-well plates and 3D-Cellusponge 96-well plates. A*STAR will be utilizing InvitroCue’s technologies to advance research on non-animal approaches to chemical safety testing under an international […]

Learn more
Published On 31 August

Preliminary Final Report

Preliminary Final Report: Download here.  

Learn more
Published On 30 August

Appendix 3B – New Issue Announcement

Appendix 3B – New issue announcement, application for quotation of additional securities and agreement: Download here.

Learn more
Published On 22 August

InvitroCue Signs Strategic Partnership Agreement With QIAGEN Suzhou

August 22, 2016 – InvitroCue Limited (ASX:IVQ) has announced that its wholly owned subsidiary InvitroCue Biomedical Service Suzhou (“InvitroCue Suzhou”) has signed a Strategic Partnership Agreement with QIAGEN Suzhou Translational Medicine Co. Limited (“QIAGEN Suzhou”).   Pursuant to the agreement, InvitroCue Suzhou and QIAGEN Suzhou will jointly accelerate the discovery of biomarkers and translational medicine […]

Learn more
Published On 16 August

Escrow Release

Escrow Release Click here to download.

Learn more
Published On 28 July

InvitroCue Announces New Program Focused on Hepatitis B Virus

July 28, 2016 – InvitroCue (ASX:IVQ), has signed a research collaboration program with Yong Loo Lin School of Medicine, National University of Singapore. The program will focus on InvitroCue’s “3D human liver” to model an in vitro system for the study of chronic Hepatitis B infection. If the program delivers promising data and results by […]

Learn more
Published On 28 July

Appendix 4C – Quarterly Report

Quarterly Report : Appendix 4C

Learn more
Published On 11 July

Investment Fact Sheet July 2016

Download the Investment Fact Sheet here.

Learn more
Published On 11 July

InvitroCue Commences Pancreatic Toxicity Assay Development

11 July 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has progressed its technology in modelling multi-organ toxicity by developing a novel assay to detect pancreatic toxicity. The assay is part of a strategic collaboration with InSphero AG (Switzerland), the world’s leading provider of assay-ready 3D microtissues for more predictive drug discovery and development. […]

Learn more
Published On 07 July

Notification of Change of Auditor

Notification of Change of Auditor Click here to download

Learn more
Published On 14 June

Investor Presentation (Mandarin)

Download the Investor Presentation translated in Simplified Mandarin. Refer to the announced English version herein.  

Learn more
Published On 24 May

InvitroCue Announces Publication of Results in Human Stem Cell Derived Hepatocytes in 3D Culture System Used in Liver Drug Testing Assays

May 24, 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has today announced that the results of the Company’s 3D Culture System for growing stem cell derived hepatocytes have been published in the May print and web editions of Molecular Pharmaceutics (Mol. Pharmaceutics). Mol. Pharmaceutics is an official peer-reviewed online scientific journal which focuses […]

Learn more
Published On 20 May

InvitroCue Convenes Scientific and Medical Advisory Board

May 20, 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has today announced the appointment of leading experts to its newly formed Scientific and Medical Advisory Board (“SAB”). The SAB will guide the company in a broad range of activities including in vitro cell-based assays, patient-derived organoids, digital pathology and medical imaging. “We are […]

Learn more
Published On 16 May

Investor Presentation 16 May 2016

Download the Investor Presentation available on Google Drive and ASX.

Learn more
Published On 16 May

InvitroCue Announces Malaria Initiative

May 16, 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, announces today a key initiative on Malaria to identify and evaluate new drug targets to tropical infectious diseases. Following its successful initiative on leishmaniasis, InvitroCue establishes an open and collaborative strategy that involves integrated partnerships and networks between academic infectious diseases institutes and pharmaceutical […]

Learn more
Published On 12 May

InvitroCue Expands 3D Cell-based Platform for Oncology

May 12, 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, announces today that it is planning to enter the oncology testing market for drugs to provide data points in selected solid tumours. Using its revolutionary 3D cell-based technology and proprietary processes, InvitroCue will be able to culture patient derived cancer cells in its laboratories […]

Learn more
Published On 27 April

Appendix 4C – Quarterly Report

Quarterly Report – Appendix 4C  

Learn more
Published On 30 March

New Issue Announcement

New Issue Announcement, Application for Quotation of Additional Securities and Agreement : Appendix 3B

Learn more
Published On 24 March

Director Appointment

Appointment of Prof. Hanry Yu as Director : Director Appointment Director Appointment

Learn more
Published On 24 March

Initial Director’s Interest Notice

Appendix 3x : Initial Director’s Interest Notice Initial Director’s Interest Notice

Learn more
Published On 23 March

New Issue Announcement

Appendix 3B : New Issue Announcement Appendix 3B    

Learn more
Published On 15 March

Becoming a Substantial Holder – Steven Fang

Form 603 : Notice of Initial Substantial Holder Steven Fang

Learn more
Published On 09 March

Agreement with London School of Hygiene & Tropical Medicine

Download the InvitroCue Agreement PDF here: Agreement

Learn more
Published On 08 March

Operations Update

Download the InvitroCue Operations Update PDF here: InvitroCue Operations Update

Learn more
Published On 29 February

Half Yearly Report

Download the Half Yearly Report and Accounts PDF here: Half Yearly Report  

Learn more
Published On 15 February

Investor Presentation

Download the InvitroCue Investor Presentation PDF here: Investor Presentation  

Learn more
Published On 08 February

Operations Update

Download the InvitroCue Operations Update PDF here: InvitroCue Operations Update

Learn more
Published On 02 February

Becoming a Substantial Holder – Hanry Yu

Form 603 – Notice of Initial Substantial Holder Hanry Yu

Learn more
Published On 02 February

Becoming a Substantial Holder – Clearbridge Accelerator

FORM 603 – Notice of Initial Substantial Holder Becoming a Substantial Holder – Clearbridge Accelerator

Learn more
Published On 22 January

Market Release: Reinstatement To Official Quotation

Download the InvitroCue Market Release PDF here: InvitroCue – Market Release

Learn more